Our Mission is to extend healthy longevity through innovative AI solutions for drug discovery and aging research.
We aspire to be a leader in the field of deep learning for drug discovery, personalized healthcare, and anti-aging interventions.
AI Pharma Pipeline
We developed a comprehensive drug discovery engine, which utilizes millions of samples and multiple data types to discover signatures of disease and identify the most promising targets for billions of molecules that already exist or can be generated
de novo with the desired set of parameters.
Integrated top-down and bottom-up target ID
and drug discovery pipelines
Pharmaceutical Pipeline Leads
Nutraceutical Pipeline Leads
Services & Collaborations
We provide services to academia, pharmaceutical and cosmetics companies:
  • Advanced deep learning solutions
  • Custom drug discovery engines
  • Custom biomarkers discovery
  • New tools for aging research
Bridging the pharmaceutical
and consumer industries
Awards & Recognition
We will provide customers with the industry-leading services, based
on our extensive experience and proven track-record in innovative
computational technology
ACS Editors' Choice
Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data
Nvidia Top 5

AI Companies for Social Impact
Nvidia GTC 2015 Finalist
Deep Learning for Drug Discovery
Most Promising Company
at the Personalized Medicine World Conference 2015 in Palo Alto, CA
106 Artificial Intelligence Startups In Healthcare
From Virtual Nurses To Drug Discovery: 106 Artificial Intelligence Startups In Healthcare
Videos about Insilico medicine
2018 AI 100 Startup: Insilico
About Insilico Medicine
Embryonic AI: Analysis of Embryonic State using Deep Neural Networks (Property of Biotime, Inc)
Chemistry AI
Life Extension Geroprotect Ageless Cell Launch
Geroprotect Partnership Between Life Extension and Insilico Medicine YouTube
Some of Our Current Projects
Insilico Medicine is committed to transforming the pharmaceutical industry with next-generation artificial intelligence.
We are developing new tools for drug discovery and repurposing, biomarker development and pursuing novel strategies
for rapid validation. Our projects combine advances in genomics, big-data analysis, deep learning and reinforcement learning.
Over 150 Academic
and Industry Collaborators Worldwide

We have a great pleasure to work with the leading companies and institutions
to provide next-level solutions for drug discovery and biomarker development.
Our News
Check out our latest news.

A ranking of the 100 most promising private artificial intelligence companies in the world

Oct. 30, 2017, London, UK: Biogerontology Research Foundation ( Chief Science Officer, Dr. Alex Zhavoronkov and Biogerontology Research Foundation Advisor and Head of Business Development for Juvenescence …

Insilico Medicine, a leader in the field of artificial intelligence, will present at the Singularity University Exponential Medicine Program in San Diego on Wednesday November 8 in Session XVIII - Future of Pharma

Insilico Medicine will present at The World Congress on Targeting Metabesity in London, UK on Tuesday, Oct. 31 in Session VIII: Are New Business Models Needed?

Insilico Medicine to use Artificial Intelligence platform to discover new Amyotrophic Lateral Sclerosis therapies.

Insilico Medicine is adapting best neural network architectures. These advances are usually integrated into a comprehensive drug discovery pipeline with the goal to enable the deep neural networks to produce perfect …

Biogerontology Research Foundation Trustee Jim Mellon announces the publication of his newest book, Juvenescence: Investing in the Age of Longevity.

Insilico Medicine
launched the Beta 1.0 version
of YOUNG.AI on September 12th, 2017

Our team is formed of bioinformatics, computational and structural biology experts, experienced medicinal chemists and deep learning engineers, who work with massive biomedical data and practical problems in drug discovery.
Alex Zhavoronkov, PhD
Qingsong Zhu, PhD
Alex Aliper
President of EMEA
Marine Bozdaganyan, PhD
Head of Medicinal Chemistry
Ivan Ozerov, PhD
Director, Drug Discovery
Quentin Vanhaelen, PhD
Director, Virtual Human Project
We have 39 scientists hired through hackathons and competitions worldwide in the US, Poland, Belgium, and Russia. Around 30% of our staff are women.
Scientific Advisory Board
Charles Cantor, PhD
ex-Director of the Human Genome Project and the Center for Advanced Biotechnology at Boston University
Michael Levitt, PhD
2013 Nobel Laureate (Chemistry) Professor, Stanford University
Bud Mishra, PhD
Professor of computer science at Courant Institute, professor of biology at Mt. Sinai School of Medicine and NYU School of Medicine
Donald Small, MD, PhD
Director of pediatric oncology at the Johns Hopkins Kimmel Cancer Center
Yuri Nikolsky, PhD
Co-founder, GeneGo, ex-VP Thomson Reuters Director, Skolkovo Found
Kristen Fortney, PhD
CEO, BioAge.
Postdoctoral fellow of Ellison Medical Foundation/American Federation for Aging Research at Stanford University
Alexey Moskalev, PhD
Professor at Syktyvkar State University
Head of the laboratory of Molecular radiobiology and gerontology at the Institute of biology of Komi Science Center of Ural division of RAS
Ulrich Muehlner, PhD
Founder at GrowthCube Partners
Previously Director Global Corporate Strategy at Novartis and with The Boston Consulting Group (BCG)
Our Publications

Upcoming Conferences
Institutional Investor AI and Longevity Forum
February 7, 2018, New York
Dr. Maharaj Conference on Transfusiology
February, 9-10, 2018, Florida, USA,
The Blockchain for Clinical Trials Forum
February 12, 2018, Orlando, Florida
AI debate at GSK House
February 20, 2018, London, UK,
Press About Us
April 23, 2017

Nvidia identifies the top 5 AI startups for social impact
Nvidia is on a quest to find the best "social impact" artificial intelligence startups as part of a program called Nvidia Inception, which is screening more than 600 entrants to cull the best AI startups in three big categories.
Read more
Contact us:
Insilico Medicine, Inc.
Emerging Technology Centers
Johns Hopkins University Eastern Campus
Suite B301, 1101 East 33rd St.
Baltimore, MD 21218

Phone: +1 443 451 7212
Fax: +1 443 451 7210